ปรัชญา: ความสำเร็จที่แท้จริงอยู่ที่การนำความรู้ไปประยุกต์ใช้เพื่อประโยชน์สุขแก่มวลมนุษยชาติ

You are here

ผลงานวิจัยหน่วยโลหิตวิทยา

Division of Hematology(หน่วยโลหิตวิทยา)

2017

  1. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry. Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Chuncharunee S, Niparuck P, Ekwattanakit S, Khuhapinant A, Norasetthada L, Nawarawong W, Makruasi N, Kanitsap N, Sirijerachai C, Chansung K, Wong P, Numbenjapon T, Prayongratana K, Suwanban T, Wongkhantee S, Praditsuktavorn P, Intragumtornchai T; Thai Lymphoma Study Group. Ann Hematol. 2017 Jan; 96(1):57-64.

2016

  1. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, Kongruang A, Limsuwanachot N, Sirirat T, Chuncharunee S, Rerkamnuaychoke B. Asian Pac J Cancer Prev. 2016 Oct 1;17(10):4647-4653.
  2. Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study. Chuncharunee S, Wong R, Rojnuckarin P, Chang CS, Chang KM, Lu MY, Hwang WL, Koh LP, Chen TY, Leung AY, Norasetthada L, Wang SC, Chang MC, Wu KH, Issaragrisil S. Int J Hematol. 2016 Oct;104(4):454-61.
  3. Multiplex RT-PCR Assay for Detection of Common Fusion Transcripts in Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Cases. Limsuwanachot N, Siriboonpiputtana T, Karntisawiwat K, Chareonsirisuthigul T, Chuncharunee S, Rerkamnuaychoke B. Asian Pac J Cancer Prev. 2016;17(2):677-84.
  4. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Satayasai W, Sirireung S, Sruamsiri R, Wahidiyat PA, Ungkanont A, Issaragrisil S, Andersson BS. Bone Marrow Transplant. 2016 Jun;51(6):813-8.
  5. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. PLoS One. 2016 Oct 28;11(10):e0164076.
  6. Cancer-associated thrombosis in Asia. Angchaisuksiri P. Thromb J. 2016 Oct 4;14(Suppl 1):26. Review.
  7. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. Weitz JI, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Nielsen JD, Goldhaber SZ, Goto S, Kayani G, Mantovani L, Prandoni P, Schellong S, Turpie AG, Kakkar AK. Thromb Haemost. 2016 Nov 30;116(6):1172-1179.
  8. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. Liew NC, Alemany GV, Angchaisuksiri P, Bang SM, Choi G, DE Silva DA, Hong JM, Lee L, Li YJ, Rajamoney GN, Suviraj J, Tan TC, Tse E, Teo LT, Visperas J, Wong RS, Lee LH. Int Angiol. 2017 Feb;36(1):1-20.
  9. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Int J Cardiol. 2016 Nov 15;223:543-547.
  10. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Lancet Haematol. 2016 Aug;3(8):e379-87.
  11. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators. Br J Haematol. 2016 Aug;174(4):610-23.
  12. International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. McLintock C, Pabinger I, Bauer KA, Laffan M, Angchaisuksiri P, Rezende SM, Middeldorp S, Ross M. J Thromb Haemost. 2016 Jan;14(1):3-27.
  13. Cyclophosphamide vs salvage chemotherapy plus G-CSF as chemo-mobilization in Asian patients undergoing autologous hematopoietic stem cell transplant. Issaragrisil S, Cheng-Hwai T, Bunworasate U, Su-Peng Y, Hung LY, Tee GY, Wahid SF, Chin NS, Puavilai T, Gin GG, Piu KL, Wen-Li H, Tsai-Yun C, Numbenjapon T. Bone Marrow Transplant. 2016 Nov 14.
  14. Low oxygen saturation and severe anemia in compound heterozygous Hb Louisville [β42(CD1)Phe→Leu] and Hb La Desirade [β129(H7)Ala→Val]. Kamseng P, Trakulsrichai S, Trachoo O, Yimniam W, Panthan B, Jittorntam P, Niparuck P, Sanguanwit P, Wananukul W, Jindadamrongwech S. Hematology. 2016 Sep 27:1-5.
  15. Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. Sparkenbaugh EM, Chantrathammachart P, Chandarajoti K, Mackman N, Key NS, Pawlinski R. Blood. 2016 Mar 10;127(10):1371-3.
  16. Alveolar Soft Part Sarcoma of Urinary Bladder Occurring as a Second Primary Malignancy: A Case Report and Literature Review. Usawachintachit M, Sitthideatphaiboon P, Thanakit V, Pukiat S, Panumatrassamee K, Opanuraks J, Santi-Ngamkun A. Case Rep Urol. 2016;2016:4746061.
  17. Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. Laureano M, Crowther M, Eikelboom J, Boonyawat K. Am J Med. 2016 Oct;129(10):e247-8.
  18. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Boonyawat K, Wang L, Lazo-Langner A, Kovacs MJ, Yeo E, Schnurr T, Schulman S, Crowther MA. Thromb Haemost. 2016 Aug 30;116(3):480-5.

2015

  1. Platelet hyperactivity in thalassemia patients with elevated tricuspid regurgitant velocity and the association with hemolysis. Srihirun S, Tanjararak N, Chuncharunee S, Sritara P, Kaewvichit R, Fucharoen S, Pattanapanyasat K, Sibmooh N. Thromb Res. 2015 Jan;135(1):121-6.
  2. A risk score for predicting pulmonary hypertension in patients with non-transfusion-dependent thalassemia in northeastern Thailand: The E-SAAN score. Teawtrakul N, Pussadhamma B, Ungprasert P, Prayalaw P, Fucharoen S, Jetsrisuparb A, Pongudom S, Sirijerachai C, Chansung K, Wanitpongpun C, Thongbuaban S, Thinkhamrop B, Chuncharunee S. Hematology. 2015 Aug;20(7):416-21.
  3. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD.Br J Haematol. 2015 Jan;168(2):284-90.
  4. The use of hematocrit level for predicting the efficiency of peripheral blood CD34(+) cell collection after G-CSF Mobilization in Healthy Donors. Pornprasertsud N, Niparuck P, Kidkarn R, Puavilai T, Sirachainan N, Pakakasama S, Hongeng S, Jootar S, Ungkanont A. J Clin Apher. 2015 Dec;30(6):329-34.
  5. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators. J Thromb Haemost. 2015 Nov;13(11):1989-98.
  6. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20.
  7. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, Klamroth R, Knoebl P, Laffan M, Mahlangu J, Miesbach W, Dalsgaard Nielsen J, Martín-Salces M, Angchaisuksiri P. J Thromb Haemost. 2015 May;13(5):743-54.
  8. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Sparkenbaugh EM, Chantrathammachart P, Wang S, Jonas W, Kirchhofer D, Gailani D, Gruber A, Kasthuri R, Key NS, Mackman N, Pawlinski R. Haematologica. 2015 Mar;100(3):308-14.
  9. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. J Thromb Haemost. 2015 Oct;13(10):1790-8.
  10. Aspirin in secondary prevention of recurrent venous thromboembolism. Boonyawat K, Crowther MA. J Thromb Thrombolysis. 2015 Apr;39(3):392-4.
  11. Venous thromboembolism prophylaxis in critically ill patients. Boonyawat K, Crowther MA. Semin Thromb Hemost. 2015 Feb;41(1):68-74.

2014

  1. Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension. Chueamuangphan N, Wongtheptian W, Patumanond J, Sukonthasarn A, Chuncharunee S, Tawichasri C, Nawarawong W.Int J Gen Med. 2014 Dec 3; 7:525-9.
  2. Implication of globin gene expression, hemoglobin F and hemoglobin E levels on β-thalassemia/Hb E disease severity. Siriworadechkul S, Jindadamrongwech S, Chuncharunee S, Aupparakkitanon S. Ann Clin Lab Sci. 2014 Fall;44(4):437-42.
  3. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Lancet Oncol. 2014 Oct;15(11):1195-206.
  4. Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension. Chueamuangphan N, Patumanond J, Wongtheptien W, Nawarawong W, Sukonthasarn A, Chuncharunee S, Tawichasri C. Int J Gen Med. 2014 Aug 19; 7:411-6.
  5. Intravascular hemolysis, vascular endothelial cell activation and thrombophilia in splenectomized patients with hemoglobin E/β-thalassemia disease. Atichartakarn V, Chuncharunee S, Archararit N, Udomsubpayakul U, Aryurachai K. Acta Haematol. 2014;132(1):100-7.
  6. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Eur J Haematol. 2014 Jun;92(6):521-6.
  7. Effect of genotype on pulmonary hypertension risk in patients with thalassemia. Teawtrakul N, Ungprasert P, Pussadhamma B, Prayalaw P, Fucharoen S, Jetsrisuparb A, Pongudom S, Sirijerachai C, Chansung K, Wanitpongpun C, Chuncharunee S. Eur J Haematol. 2014;92(5):429-34.
  8. Prevalence and risk factors for pulmonary hypertension in patients with hemoglobin E/β-thalassemia disease. Atichartakarn V, Chuncharunee S, Archararit N, Udomsubpayakul U, Lee R, Tunhasiriwet A, Aryurachai K. Eur J Haematol. 2014 Apr;92(4):346-53.
  9. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Pongtanakul B, Rujkijyanont P, Meekaewkunchorn A, Sruamsiri R, Ungkanont A, Issaragrisil S, Andersson BS, Hongeng S. Biol Blood Marrow Transplant. 2014 Dec;20(12):2066-71.
  10. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C; paradigm 2 Investigators. Blood. 2014 Dec 18;124(26):3880-6. 
  11. Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients. Boonyawat K, Angchaisuksiri P, Aryurachai K, Chaiyaroj S, Ahmadi Z, Chong BH. Thromb Res. 2014 Nov;134(5):957-62.
  12. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators. J Thromb Haemost. 2014 Aug;12(8):1244-53.
  13. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel RP, Monroe DM, Mackman N, Key NS, Pawlinski R. Blood. 2014 Mar 13;123(11):1747-56.
  14. Hydroxyurea and colonic ulcers: a case report. Boonyawat K, Wongwaisayawan S, Nitiyanant P, Atichartakarn V. BMC Gastroenterol. 2014 Jul 31;14:134.

2013

  1. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD. Ann Hematol. 2013 Nov; 92(11):1485-93.
  2. Pulmonary artery pressure correlates directly with spleen volume in non-splenectomized hemoglobin E/β-thalassemia patients. Atichartakarn V, Chuncharunee S, Yamwong S, Yingchoncharoen T, Jongjirasiri S, Archararit N, Udomsubpayakul U. Acta Haematol. 2013; 130(3):172-5.
  3. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD. Am J Hematol. 2013 Jun; 88 (6):503-6.
  4. Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N, Chuncharunee S. J Pediatr Hematol Oncol. 2013 Apr; 35 (3):212-7.
  5. Correction of coagulation and inflammation activation by chronic blood transfusion in an asplenic patient with haemoglobin E/β-thalassaemia and pulmonary arterial hypertension. Chuncharunee S, Atichartakarn V, Archararit N, Aryurachai K. Transfus Med. 2013 Aug; 23 (4):276-8.
  6. Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability. Intragumtornchai T, Bunworasate U, Siritanaratkul N, Khuhapinant A, Nawarawong W, Norasetthada L, Lekhakula A, Rujirojindakul P, Sirijerachai C, Chansung K, Suwanban T, Chuncharunee S, Niparuck P, Wongkhantee S, Mongkonsritragoon W, Numbenjapon T. Leuk Lymphoma. 2013 Jan; 54 (1):83-9.
  7. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G. Leuk Res. 2013 Feb 12.
  8. High-value, cost-conscious care. Atichartakarn V. Ann Intern Med. 2013 Jan 15; 158(2):143.
  9. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Anurathapan U, Pakakasama S, Rujkijyanont P, Sirachainan N, Songdej D, Chuansumrit A, Sirireung S, Charoenkwan P, Jetsrisuparb A, Issaragrisil S, Ungkanont A, Sruamsiri R, Srisala S, Andersson BS, Hongeng S. Biol Blood Marrow Transplant. 2013 Aug;19(8):1259-62.
  10. Tropical hemostasis/thrombosis. Angchaisuksiri P, Chuansumrit A. Thromb Res. 2013;132(6):635-6.
  11. Coagulopathy in malaria. Angchaisuksiri P. Thromb Res. 2014 Jan;133(1):5-9.
  12. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. Hokusai-VTE Investigators., Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. N Engl J Med. 2013 Oct 10;369(15):1406-15.
  13. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, Rossi E, Folsom AR, Almawi WY, Scarabin PY, den Heijer M, Cushman M, Penco S, Vaya A, Angchaisuksiri P, Okumus G, Gemmati D, Cima S, Akar N, Oguzulgen KI, Ducros V, Lichy C, Fernandez-Miranda C, Szczeklik A, Nieto JA, Torres JD, Le Cam-Duchez V, Ivanov P, Cantu-Brito C, Shmeleva VM, Stegnar M, Ogunyemi D, Eid SS, Nicolotti N, De Feo E, Ricciardi W, Boccia S. Eur J Epidemiol. 2013 Aug;28(8):621-47.
  14. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators.; RE-SONATE Trial Investigators. N Engl J Med. 2013 Feb 21;368(8):709-18.
  15. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G. Leuk Res. 2013 May;37(5):520-30.

2012

  1. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Blood. 2012 Aug 2; 120(5): 970-7.
  2. Nondeletional Hb Queens Park [α32(B13)Met→Lys]/Hb H (β4) disease. Sroymora S, Jindadamrongwech S, Butthep P, Chuncharunee S. Hemoglobin. 2012; 36(3): 293-8.
  3. Clinical indicators for pulmonary arterial hypertension in thalassemia. Chueamuangphan N, Wongtheptien W, Nawarawong W, Sukornthasarn A, Chuncharunee S, Tawichasri C, Patumanond J. J Med Assoc Thai. 2012 Jan; 95(1): 16-21.
  4. A rare Hb H disease due to the - -(SEA) and 16.6 kb α-thalassemia-2 deletions. Sroymora S, Jindadamrongwech S, Butthep P, Chuncharunee S. Hemoglobin. 2012; 36(2):200-4.
  5. Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia. Praditpornsilpa K, Tiranathanakul K, Jootar S, Tungsanga K, Eiam-Ong S. Clin Nephrol. 2012 Oct 30.
  6. Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations. Tangnararatchakit K, Tirapanich W, Anurathapan U, Tapaneya-Olarn W, Pakakasama S, Jootar S, Slavin S, Hongeng S. Pediatr Transplant. 2012 Dec; 16(8):E342-7.
  7. CML treatment in Asia-Pacific region. Jootar S. Hematology. 2012 Apr;17 Suppl 1:S72-4.
  8. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Pongpruttipan T, Sukpanichnant S, Assanasen T, Wannakrairot P, Boonsakan P, Kanoksil W, Kayasut K, Mitarnun W, Khuhapinant A, Bunworasate U, Puavilai T, Bedavanija A, Garcia-Herrera A, Campo E, Cook JR, Choi J, Swerdlow SH. Am J Surg Pathol. 2012 Apr; 36(4):481-99.
  9. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Leuk Lymphoma. 2012 May;53(5):907-14.
  10. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Nicolini FE, Turkina A, Shen ZX, Gallagher N, Jootar S, Powell BL, De Souza C, Zheng M, Szczudlo T, le Coutre P. Cancer. 2012 Jan 1;118(1):118-26.
  11. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. EINSTEIN–PE Investigators., Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. N Engl J Med. 2012 Apr 5;366(14):1287-97.
  12. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF. Thromb Haemost. 2012 Feb;107(2):232-40.
  13. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Chantrathammachart P, Mackman N, Sparkenbaugh E, Wang JG, Parise LV, Kirchhofer D, Key NS, Pawlinski R. Blood. 2012 Jul 19;120(3):636-46.
  14. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Chang JY, Chantrathammachart P, Monroe DM, Key NS. Thromb Res. 2012 Sep;130(3):e151-7.
  15. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, Kirchhofer D, Bogdanov VY, Bach RR, Rak J, Church FC, Wolberg AS, Pawlinski R, Key NS, Yeh JJ, Mackman N. Blood. 2012 Jun 7;119(23):5543-52.
  16. Tissue factor and thrombin in sickle cell anemia. Chantrathammachart P, Pawlinski R. Thromb Res. 2012 May;129 Suppl 2:S70-2.

2011 

  1. Activation of mononuclear phagocytes and its relationship to asplenia and phosphatidylserine exposing red blood cells in hemoglobin E/β-thalassemia patients. Banyatsuppasin W, Butthep P, Atichartakarn V, Thakkinstian A, Archararit N, Pattanapanyasat K, Chuncharunee S. Am J Hematol. 2011 Jan; 86(1):89-92.
  2. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Leuk Lymphoma. 2011 Dec 5.
  3. Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Nicolini FE, Turkina A, Shen ZX, Gallagher N, Jootar S, Powell BL, De Souza C, Zheng M, Szczudlo T, le Coutre P. Cancer. 2011 Jul 5.
  4. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S. Kidney Int. 2011 Jul; 80(1):88-92. Epub 2011 Mar 23.
  5. DNA detection of chronic myelogenous leukemia by magnetic nanoparticles. Jangpatarapongsa K, Polpanich D, Yamkamon V, Dittharot Y, Peng-On J, Thiramanas R, Hongeng S, Jootar S, Charoenmak L, Tangboriboonrat P. Analyst. 2011 Jan 21;136(2):354-8. Epub 2010 Oct 21.
  6. Sarcoidosis-associated MHC Ags and the development of cutaneous and nodal granulomas following allogeneic hematopoietic cell transplant. Pukiat S, McCarthy PL Jr, Hahn T, Morrison C, Shanahan T, Qiu J, Liu H. Bone Marrow Transplant. 2011 Jul;46(7):1032-4.

2010

  1. DNA detection of chronic myelogenous leukemia by magnetic nanoparticles. Jangpatarapongsa K, Polpanich D, Yamkamon V, Dittharot Y, Peng-On J, Thiramanas R, Hongeng S, Jootar S, Charoenmak L, Tangboriboonrat P. Analyst. 2011 Jan 21;136(2):354-8. Epub 2010 Oct 21.
  2. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients. Niparuck P, Kanoksil W, Chuncharunee S, Boonsakan P, Ungkanont A, Angchaisuksiri P, Karntisaviwat K, Apilugsanachit A, Rerkamnuatchoke B, Jootar S, Nitiyanant P, Atichartakarn V. Leuk Lymphoma. 2010 Nov; 51(11):2120-5. Epub 2010 Sep 17. 
  3. Transcoronary infusion of bone marrow derived multipotent stem cells to preserve left ventricular geometry and function after myocardial infarction. Boonbaichaiyapruck S, Pienvichit P, Limpijarnkij T, Rerkpattanapipat P, Pongpatananurak A, Saelee R, Ungkanont A, Hongeng S. Clin Cardiol. 2010 Jul; 33(7): E10-5.
  4. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R. Leuk Res. 2010 Nov; 34(11): 1459-71.
  5. Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. Niparuck P, Sorakhunpipitkul L, Atichartakarn V, Chuncharunee S, Ungkanont A, Aungchaisuksiri P, Puavilai T, Jootar S. J Hematol Oncol. 2010 Jan 5;3:1.
  6. Intravascular B-cell lymphoma presenting with cauda equina syndrome: the role of skin biopsy. Piyatanont K, Bamrungrak K, Watcharananan S, Sathapatayavongs B, Chuncharunee S, Larbcharoensub N, Witoonpanich R. Eur J Dermatol. 2010 Nov-Dec;20(6):821-2.
  7. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, Au WY, Chu WC, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pennell DJ. J Magn Reson Imaging. 2010 Aug;32(2):315-9.
  8. Hb Tak and Hb Q-Thailand in Thai patients are S-window hemoglobin variants revealed by high performance liquid chromatography. Jindadamrongwech S, Tungbuppha N, Chuncharunee S, Butthep P. Hemoglobin. 2010 Jan;34(2):161-4.
  9. Oral rivaroxaban for symptomatic venous thromboembolism. EINSTEIN Investigators., Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. N Engl J Med. 2010 Dec 23;363(26):2499-510.
  10. Integration of genetic, clinical, and INR data to refine warfarin dosing. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Clin Pharmacol Ther. 2010 May;87(5):572-8.
  11. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Anderson FA Jr; ENDORSE Investigators. Thromb Haemost. 2010 Apr;103(4):736-48.
  12. Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors. Chuansumrit A, Angchaisuksiri P, Sirachainan N. J Blood Med. 2010;1:37-48.
  13. Membrane microparticles in VTE and cancer. Key NS, Chantrathammachart P, Moody PW, Chang JY. Thromb Res. 2010 Apr;125 Suppl 2:S80-3. doi: 10.1016/S0049-3848(10)70020-7. Review.
  14. Diffuse large B-cell lymphoma presenting as pancoast tumor. Ngamphaiboon N, Pukiat S, Kandimalla Y, Hernandez-Ilizaliturri FJ, Rooney JJ. J Clin Oncol. 2010 Jun 1;28(16):e254-6.

2009

  1. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V. J Med Assoc Thai. 2009 Sep;92(9):1143-9.

  2. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Cancer. 2009 Sep 15;115(18):4136-47.

  3. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Kim DW, Goh YT, Hsiao HH, Caguioa PB, Kim D, Kim WS, Saikia T, Agrawal S, Roy A, Dai D, Bradley-Garelik MB, Mukhopadhyay J, Jootar S.  Int J Hematol. 2009 Jun;89(5):664-72.

  4. Chronic myeloid leukemia in Asia. Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O'Neil WM, Saikia TK, Wang J. Int J Hematol. 2009 Jan;89(1):14-23.

  5. The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions. Niparuck P, Ungkanont A, Ativitavas T, Jootar S. Bone Marrow Transplant. 2009 Jun;43(11):887-9.

  6. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, Pongskul C, Prasithsirikul W, Achavanuntakul B, Ruangkarnchanasetr P, Laohavinij S, Eiam-Ong S. Nephrol Dial Transplant. 2009 May;24(5):1545-9.

2008

  1. Successful treatment of acquired amegakaryocytic thrombocytopenic purpura refractory to corticosteroids and intravenous immunoglobulin with antithymocyte globulin and cyclosporin. Niparuck P, Atichartakarn V, Chuncharunee S. Int J Hematol. 2008 Sep;88(2):223-6.
  2. A scoring system for the classification of beta-thalassemia/Hb E disease severity. Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, Chuncharunee S, Chantrakoon N, Boonmongkol P, Winichagoon P, Fucharoen S. Am J Hematol. 2008 Jun;83(6):482-4.

2007

  1. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Sura T, Ungkanont A, Chuncharunee S, Jootar S, Issaragisil S. Am J Hematol. 2007 Dec;82(12):1095-8.
  2. Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease. Angchaisuksiri P, Atichartakarn V, Aryurachai K, Archararit N, Chuncharunee S, Tiraganjana A, Rattanasiri S. Am J Hematol. 2007 Nov;82(11):1001-4.
  3. Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review. Jirapinyo M, Manonai J, Herabutya Y, Chuncharunee S. J Med Assoc Thai. 2007 May;90(5):977-81. Review.
  4. A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor. Sobhonslidsuk A, Ungkanont A.World J Gastroenterol. 2007 Feb 21;13(7):1138-40.
  5. Risk factors of venous thromboembolism in thai patients. Angchaisuksiri P, Atichartakarn V, Aryurachai K, Archararit N, Rachakom B, Atamasirikul K, Tiraganjana A. Int J Hematol. 2007 Dec;86(5):397-402.
  6. Venous thromboembolism in Thai children. Sirachainan N, Chuansumrit A, Angchaisuksiri P, Pakakasama S, Hongeng S, Kadegasem P. Pediatr Hematol Oncol. 2007 Jun;24(4):245-56.
  7. Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome. Parkpian V, Verasertniyom O, Vanichapuntu M, Totemchokchyakarn K, Nantiruj K, Pisitkul P, Angchaisuksiri P, Archararit N, Rachakom B, Ayurachai K, Janwityanujit S. Clin Rheumatol. 2007 Oct;26(10):1663-70.

2006

  1. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Jootar S, Pornprasertsud N, Petvises S, Rerkamnuaychoke B, Disthabanchong S, Pakakasama S, Ungkanont A, Hongeng S. Leuk Res. 2006 Dec;30(12):1493-8.
  2. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U, Ungkanont A, Jootar S. Biol Blood Marrow Transplant. 2006 Jun;12(6):683-7.
  3. Single nucleotide polymorphisms and haplotypes of protein C and protein S genes in the Thai population. Chumpia W, Peerapittayamongkol C, Angchaisuksiri P, Komanasin N, Muta K, Kuaha K, Iida H, Inoue S, Wada Y, Kurihara M, Hamasaki N, Fucharoen S. Blood Coagul Fibrinolysis. 2006 Jan;17(1):13-8.
  4. Massive hemothorax in a beta-thalassemic patient due to spontaneous rupture of extramedullary hematopoietic masses: diagnosis and successful treatment. Pornsuriyasak P, Suwatanapongched T, Wangsuppasawad N, Ngodngamthaweesuk M, Angchaisuksiri P. Respir Care. 2006 Mar;51(3):272-6.

2005

2004

  1. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient. Atichartakarn V, Chuncharunee S, Chandanamattha P, Likittanasombat K, Aryurachai K. Blood. 2004 Apr 1;103(7):2844-6.
  2. Nonmyeloablative stem cell transplantation with a haploidentical donor in a class 3 lucarelli severe thalassemia patient. Hongeng S, Pakakasama S, Chaisiripoomkere W, Ungkanont A, Jootar S. Bone Marrow Transplant. 2004 Aug;34(3):271-2.
  3. Outcome of transplantation with unrelated donor bone marrow in children with severe thalassaemia. Hongeng S, Pakakasama S, Chaisiripoomkere W, Chuansumrit A, Sirachainan N, Ungkanont A, Jootar S. Bone Marrow Transplant. 2004 Feb;33(4):377-9.
  4. National survey of patients with hemophilia and other congenital bleeding disorders in Thailand. Chuansumrit A, Mahasandana C, Chinthammitr Y, Pongtanakul B, Laossombat V, Nawarawong W, Lektakul Y, Wangruangsatid S, Sriboriboonsin L, Rojnakarin P, Angchaisuksiri P; Hemophilia Study Group. Southeast Asian J Trop Med Public Health. 2004 Jun;35(2):445-9.
  5. Acquired bleeding disorders: the impact of health problems in the developing world. Isarangkura P, Mahasandana C, Chuansumrit A, Angchaisuksiri P. Haemophilia. 2004 Oct;10 Suppl 4:188-95. Review.
  6. Survival analysis of patients with haemophilia at the International Haemophilia Training Centre, Bangkok, Thailand. Chuansumrit A, Krasaesub S, Angchaisuksiri P, Hathirat P, Isarangkura P. Haemophilia. 2004 Sep;10(5):542-9.

2003

  1. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, Aryurachai K. Int J Hematol. 2003 Aug;78(2):139-45.
  2. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. Int J Hematol. 2003 Apr;77(3):299-303.
  3. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood. Carr ME Jr, Angchaisuksiri P, Carr SL, Martin EJ. Cell Biochem Biophys. 2003;39(2):89-99.
  4. Abnormalities in bone mineral density and bone histology in thalassemia. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R. J Bone Miner Res. 2003 Sep;18(9):1682-8.

2002

  1. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, Atamasirikul K. Br J Haematol. 2002 Sep;118(3):893-8.
  2. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Hongeng S, Tardtong P, Worapongpaiboon S, Ungkanont A, Jootar S. Bone Marrow Transplant. 2002 May;29(10):871-2.
  3. Secretion of a unique peptide from interleukin-2-stimulated natural killer cells that induces endomitosis in immature human megakaryocytes. Angchaisuksiri P, Grigus SR, Carlson PL, Krystal GW, Dessypris EN. Blood. 2002 Jan 1;99(1):130-6.

2001

  1. Effect of G-CSF on peripheral blood progenitor cell mobilization and collection from healthy donors. Chaisiripoomkere W, Jootar S, Ungkanont A. Asian Pac J Allergy Immunol. 2001 Sep;19(3):183-90.
  2. Host origin of marrow mesenchymal stem cells following allogeneic cord-blood stem-cell transplantation. Hongeng S, Petvises S, Rerkamnuaychoke B, Worapongpaiboon S, Tardtong P, Apibal S, Ungkanont A. Int J Hematol. 2001 Aug;74(2):235-6.

2000

  1. High dose chemotherapy and peripheral blood stem cell transplantation for high risk primary breast cancer: a single center experience in Thailand. Ungkanont A, Jootar S, Ratanatharathorn V, Chiernsilp A. Asian Pac J Allergy Immunol. 2000 Dec;18(4):215-20.
  2. Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. Ungkanont A, Mongkonsritrakoon W, Jootar S, Srichaikul T. Bone Marrow Transplant. 2000 Dec;26(12):1351-4.
  3. Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis. Chuncharunee S, Archararit N, Ungkanont A, Jootar S, Angchaisuksiri P, Bunyaratavej A, Rojanasthein S, Atichartakarn V. J Med Assoc Thai. 2000 Mar;83 Suppl 1:S95-100.
  4. Nursing roles in orthopaedic joint correction in haemophiliac patients. Kuhathong K, Chuansumrit A, Keorochana S, Pornpipatpong N, Pitakjaroen M, Suwannurak M, Angchaisuksiri P, Isarangkura P. Haemophilia. 2000 Nov;6(6):672-6.
  5. Prevalence of the C677T methylenetetrahydrofolate reductase mutation in Thai patients with deep vein thrombosis. Angchaisuksiri P, Pingsuthiwong S, Sura T, Aryuchai K, Busabaratana M, Atichartakarn V. Acta Haematol. 2000;103(4):191-6.
  6. Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Angchaisuksiri P, Pingsuthiwong S, Aryuchai K, Busabaratana M, Sura T, Atichartakarn V, Sritara P. Am J Hematol. 2000 Oct;65(2):119-22.
  7. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Chuansumrit A, Isarangkura P, Angchaisuksiri P, Sriudomporn N, Tanpowpong K, Hathirat P, Jorgensen LN. Haemophilia. 2000 Mar;6(2):61-5.

1999

  1. Serum erythropoietin levels in thalassemia major and intermedia. Chaisiripoomkere W, Jootar S, Chancharunee S, Ungkanont A. Southeast Asian J Trop Med Public Health. 1999 Dec;30(4):786-8.
  2. Study of hematopoietic progenitor cells, hematological values and lymphocyte subsets in cord blood: application for cord blood transplantation. Chaisiripoomkere W, Jootar S, Ungkanont A, Jaovisidha A, Onpun S, Khupulsup K. Southeast Asian J Trop Med Public Health. 1999 Dec;30(4):781-5.
  3. Delayed administration of G-CSF in both mobilization and post transplantation in autologous peripheral blood stem cell transplantation. Ungkanont A, Jootar S, Chuncharunee S, Chaisiripoomkere W. Asian Pac J Allergy Immunol. 1999 Dec;17(4):289-93.
  4. Allogeneic peripheral blood stem cell transplantation in a Wiskott-Aldrich syndrome patient. Hongeng S, Pakakasama S, Hathirat P, Chaisiripoomkere W, Ungkanont A. Bone Marrow Transplant. 1999 Aug;24(4):445-6.
  5. Indices of iron status in continuous ambulatory peritoneal dialysis patients. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, Ungkanont A, Bunyaratvej A. Am J Kidney Dis. 1999 Jul;34(1):29-35.

1998

  1. Allogeneic bone marrow transplantation in an osteopetrosis patient: first report in Thailand. Hongeng S, Pakakasama S, Chuansumrit A, Rerkamnuaychoke B, Nitiyanunt P, Suthutvoravut U, Ungkanont A, Hathirat P. Asian Pac J Allergy Immunol. 1998 Dec;16(4):193-8

1996

  1. Multivariate analysis of prognostic factors in Philadelphia chromosome positive chronic myeloid leukemia: an update of the first series in Thailand. Jootar S, Ungkanont A, Chuncharunee S, Atichartakarn V. Asian Pac J Allergy Immunol. 1996 Jun;14(1):25-30.
  2. Use of plasma exchange in hereditary deficiency of factor V and factor VIII. Sallah AS, Angchaisuksiri P, Roberts HR. Am J Hematol. 1996 Jul;52(3):229-30.
  3. Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Angchaisuksiri P, Carlson PL, Dessypris EN. Br J Haematol. 1996 Apr;93(1):13-7.

1994

  1. Replication and endoreplication in developing megakaryocytes in vitro. Angchaisuksiri P, Carlson PL, Day EB, Dessypris EN. Exp Hematol. 1994 Jul;22(7):546-50.

1993

  1. Experience with factor VIII: C inhibitors and acquired von Willebrand's disease in an adult at Ramathibodi Hospital. Angchaisuksiri P, Atichartakarn V, Pathepchotiwong K, Jootar S, Ungkanont A, Chuncharunee S. Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:152-8.
  2. HIV infection after autologous bone marrow transplantation despite HIV-antibody and HIV-antigen screening. Jootar S, Angchaisuksiri P, Chiewsilp P, Sathapatayavongs B, Chuncharunee S, Tanprasert S. Bone Marrow Transplant. 1993 Aug;12(2):167-8.

1992

  1. Bone marrow transplantation in Ramathibodi Hospital: progress report. Jootar S, Chuncharunee S, Ungkanont A, Tanapothiwirut W, Chiewsilp P. Asian Pac J Allergy Immunol. 1992 Dec;10(2):117-22.
  2. Anti-HIV seroconversion in hemophilia A patient after transfusion of anti-HIV negative blood components. Ungkanont A, Atichartakarn V, Chiewsilp P. J Med Assoc Thai. 1992 Feb;75(2):120-2.